Henri Riey - Sartorius Stedim Non-Executive Independent Director
| SDMHF Stock | USD 207.75 12.25 5.57% |
Director
Mr. Henri Riey has served as NonExecutive Independent Director of Sartorius Stedim Biotech SA as of June 29, 2007. He is also Member of the Remuneration and Nominating Committee and since December 5, 2007 he has served as Chairman of Company Audit Committee since 2007.
| Age | 56 |
| Tenure | 17 years |
| Phone | 33 4 42 84 56 00 |
| Web | https://www.sartorius.com |
Sartorius Stedim Management Efficiency
The company has return on total asset (ROA) of 0.1389 % which means that it generated a profit of $0.1389 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3306 %, meaning that it generated $0.3306 on every $100 dollars invested by stockholders. Sartorius Stedim's management efficiency ratios could be used to measure how well Sartorius Stedim manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 14 records | DIRECTOR Age | ||
| Paul Richins | Utah Medical Products | 56 | |
| Yoseph Bornstein | Microbot Medical | 65 | |
| Yoav Waizer | Microbot Medical | 51 | |
| James Beeson | Utah Medical Products | 75 | |
| Ernst Hoyer | Utah Medical Products | 79 | |
| Barbara Payne | Utah Medical Products | 70 | |
| Solomon Mayer | Microbot Medical | 62 | |
| Frank DiPasquale | Innovative Eyewear | 52 | |
| Moshe Shoham | Microbot Medical | 64 | |
| Scott Burell | Microbot Medical | 52 | |
| George Bell | Innovative Eyewear | 57 | |
| Martin Madden | Microbot Medical | 57 | |
| Ralph Singer | Innovative Eyewear | 59 | |
| Prattipati Laxminarain | Microbot Medical | 59 | |
Management Performance
| Return On Equity | 0.33 | |||
| Return On Asset | 0.14 |
Sartorius Stedim Biotech Leadership Team
Elected by the shareholders, the Sartorius Stedim's board of directors comprises two types of representatives: Sartorius Stedim inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sartorius. The board's role is to monitor Sartorius Stedim's management team and ensure that shareholders' interests are well served. Sartorius Stedim's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sartorius Stedim's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andreas Theisen, Director of Investor Relations | ||
| Reinhard Vogt, Executive VP of Marketing Sales and Services and Director | ||
| AnneMarie Graffin, Non-Executive Independent Director | ||
| Petra Kirchhoff, Vice President of Corporate Communications and Investor Relations | ||
| Henri Riey, Non-Executive Independent Director | ||
| Michael Melingo, Deputy CEO - Marketing, Services and Business Development | ||
| OscarWerner Reif, Deputy CEO - Research and Development, Member of the Executive Committee and Executive Director | ||
| Olivier Guitard, Head BPS | ||
| Joachim Kreuzburg, Chairman of The Board and CEO | ||
| Volker Niebel, Executive VP of Operations and IT and Director | ||
| Bernard Lemaitre, Non-Executive Director | ||
| Susan Dexter, Non-Executive Independent Director | ||
| Heiko Imhl, VP Relations | ||
| Arnold Picot, Chairman of Supervisory Board, Member of The Admin. Board, Non Executive Director, Chairman of Remuneration Committee and Member of Audit Committee | ||
| Lothar Kappich, Director | ||
| Joerg Pfirrmann, Member of the Executive Committee - Finance, Information Technology, Human Resources | ||
| Benedikt Orzelek, Investor Relations Contact | ||
| John Mackay, Sales Marketing | ||
| Liliane Lassus, Non-Executive Director |
Sartorius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sartorius Stedim a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.33 | |||
| Return On Asset | 0.14 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 32.97 B | |||
| Shares Outstanding | 92.17 M | |||
| Shares Owned By Insiders | 73.81 % | |||
| Shares Owned By Institutions | 13.73 % | |||
| Price To Earning | 60.34 X | |||
| Price To Book | 13.58 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sartorius Stedim Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Sartorius Stedim Biotech information on this page should be used as a complementary analysis to other Sartorius Stedim's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for Sartorius Pink Sheet analysis
When running Sartorius Stedim's price analysis, check to measure Sartorius Stedim's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sartorius Stedim is operating at the current time. Most of Sartorius Stedim's value examination focuses on studying past and present price action to predict the probability of Sartorius Stedim's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sartorius Stedim's price. Additionally, you may evaluate how the addition of Sartorius Stedim to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |